Clinical and demographic features of patients with moderate to severe active systemic lupus erythematosus in Russia

Trial Identifier: D3461R00092
Sponsor: AstraZeneca
Start Date: April 2024
Primary Completion Date: September 2025
Study Completion Date: September 2025
Condition: Lupus

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
Russia Barnaul, Russia
Russia Belgorod, Russia
Russia Chelyabinsk, Russia
Russia Ekaterinburg, Russia
Russia Grozny, Russia
Russia Irkutsk, Russia
Russia Izhevsk, Russia
Russia Kaliningrad, Russia
Russia Kazan, Russia
Russia Kemerovo, Russia
Russia Krasnodar, Russia
Russia Makhachkala, Russia
Russia Moscow, Russia
Russia Murmansk, Russia
Russia Nizny Novgorod, Russia
Russia Novosibirsk, Russia
Russia Omsk, Russia
Russia Orenburg, Russia
Russia Penza, Russia
Russia Perm, Russia
Russia Petrozavodsk, Russia
Russia Ryazan, Russia
Russia Saint-Petrburg, Russia
Russia Samara, Russia
Russia Saransk, Russia
Russia Saratov, Russia
Russia Surgut, Russia
Russia Tula, Russia
Russia Ufa, Russia
Russia Ulianovsk, Russia
Russia Volgograd, Russia
Russia Yaroslavl, Russia